Study guide

2.6 DSCSA & Drug Supply Chain Integrity

Pennsylvania MPJE Pharmacy Jurisprudence Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the PA MPJE Exam 1.2 How to Use This Study Guide

2 Federal Pharmacy Law Foundations

2.1 Controlled Substances Act & DEA Scheduling 2.2 DEA Forms, Registration & Security 2.3 Federal Food, Drug, and Cosmetic Act 2.4 HIPAA & Patient Privacy 2.5 OBRA '90, Medicare/Medicaid & DUR 2.6 DSCSA & Drug Supply Chain Integrity

3 Area 1: Licensure & Personnel (22%)

3.1 Pharmacist Licensure & the PA Board of Pharmacy 3.2 Pharmacist-in-Charge Responsibilities 3.3 Pharmacy Interns & Practical Experience 3.4 Pharmacy Technicians & Trainees (PA Registration) 3.5 License Renewal, CE & Discipline 3.6 Impaired-Pharmacist Programs & Mandatory Reporting

4 Area 2: Pharmacist Practice (33%)

4.1 Prescription Requirements & Practitioner Authority 4.2 Controlled Substance Prescribing (Federal + PA) 4.3 Refills & Authority Limitations 4.4 Drug Administration & Collaborative Practice Agreements 4.5 Patient Counseling & Documentation 4.6 Returning & Reusing Drugs 4.7 Immunizations, Naloxone & Public Health 4.8 Patient Confidentiality & Pharmacy Records

5 Area 3: Dispensing Requirements (24%)

5.1 Legitimate Medical Purpose Verification 5.2 Prescription Transfers Between Pharmacies 5.3 Prospective DUR & the PA PDMP (ABC-MAP) 5.4 Refill Exceptions & Emergency Dispensing 5.5 Labeling of Dispensed Drugs 5.6 Packaging of Dispensed Drugs 5.7 Drugs & Conditions Prohibiting Dispensing 5.8 OTC, Behind-the-Counter & Hazardous Drugs

6 Area 4: Pharmacy Operations (21%)

6.1 Ordering, Acquisition & Distribution Records 6.2 Recordkeeping, Storage & Handling 6.3 Controlled Substance Inventories 6.4 Delivery of Drugs 6.5 Product Selection & Generic Substitution 6.6 Compounding: Sterile, Nonsterile & Hazardous 6.7 Central Fill & Centralized Prescription Processing 6.8 Pharmacy Permits, Inspections & Discipline

7 Test-Day Strategy & Final Review

7.1 When PA Law Is Stricter Than Federal Law 7.2 Test-Day Strategy & Common Traps

2.6 DSCSA & Drug Supply Chain Integrity

Key Takeaways Explain This Topic AI

The Drug Supply Chain Security Act (DSCSA), Title II of the Drug Quality and Security Act of 2013, requires an interoperable electronic system to trace prescription drugs through the U.S. supply chain.

DSCSA trading partners are manufacturers, repackagers, wholesale distributors, third-party logistics providers (3PLs), and dispensers (including pharmacies); each must be authorized and licensed.

Pharmacies must not accept a prescription product without the required Transaction Information and Transaction Statement (FDA says the Transaction History requirement effectively ended November 27, 2023).

FDA's DSCSA stabilization period ended November 27, 2024; the enhanced electronic requirements now apply to every trading partner except small dispensers, which are exempt from certain of them until November 27, 2027.

Pharmacies must investigate suspect products, quarantine illegitimate products, and notify FDA and trading partners within 24 hours of confirming an illegitimate product.

Last updated: November 2026

DSCSA & Drug Supply Chain Integrity

The Drug Supply Chain Security Act (DSCSA) , enacted in 2013 as Title II of the Drug Quality and Security Act, requires the FDA to build an interoperable, electronic, package-level system to trace prescription drug products through the U.S. supply chain. The goal is to detect and remove suspect and illegitimate products—counterfeits, diverted, recalled, or otherwise unsafe. For the PA MPJE, you must know the trading-partner definitions, the two tracing documents (TI and TS), the end of FDA's stabilization period on November 27, 2024, the small-dispenser exemption to November 27, 2027, and the suspect/illegitimate product workflow.

Trading Partners

The DSCSA defines five categories of trading partners . Each must be authorized by FDA or the relevant state authority, and trading with an unauthorized source is prohibited.

Trading Partner Definition Authorization

Manufacturer Entity that holds an approved NDA/ANDA/BLA or otherwise manufactures a prescription drug for sale FDA registration and drug listing

Repackager Entity that repacks and relabels a product or package for further sale or distribution FDA registration

Wholesale distributor Entity (other than the manufacturer) that distributes prescription drugs to persons other than the consumer or patient State license; in PA, the Board of Pharmacy and Dept. of Health regulate wholesale distributor licensure

Third-party logistics provider (3PL) Entity that provides logistics services (warehousing, distribution) on behalf of a manufacturer or wholesale distributor State license; FDA does not register 3PLs as manufacturers

Dispenser Entity that dispenses prescription drugs to patients or consumers—includes pharmacies, pharmacists, and practitioners dispensing from offices State pharmacy permit/license; DEA registration if dispensing controlled substances

Important

A pharmacy is a dispenser under DSCSA. A pharmacy cannot lawfully acquire a DSCSA-covered prescription product from anyone other than an authorized trading partner. Buying from an unlicensed wholesaler or an internet source outside the regulated supply chain is prohibited. A pharmacy that sells stock to another pharmacy is engaged in wholesale distribution, which requires a wholesale distributor license (21 U.S.C. § 353(e)(1)), unless an exclusion in 21 U.S.C. § 353(e)(4) applies, such as intracompany or common-control transfers or minimal quantities sold to a practitioner for office use.

Product Tracing: TI and TS

The DSCSA requires trading partners to pass product tracing information with each transaction (sale, transfer, or return of a covered prescription drug). The tracing documents, defined at 21 U.S.C. § 360eee, are TI and TS (TH is shown for reference):

Tracing Document Required Content

Transaction Information (TI) Product name, NDC, strength, dosage form, container size, number of containers, lot number, ship date, expiration date; and the name and address of the trading partner from whom the product was received and to whom it was shipped

Transaction History (TH) The list of all transactions going back to the manufacturer; FDA says the requirement to provide and receive it effectively ended November 27, 2023

Transaction Statement (TS) A statement by the seller that it is authorized, received the product from an authorized person, received TI and a TS from the prior owner, did not knowingly ship a suspect or illegitimate product, had systems to comply with verification requirements, did not knowingly provide false transaction information, and did not knowingly alter the transaction history

Under the enhanced requirements, TI and TS must be exchanged in a secure, interoperable electronic form (e.g., EPCIS data tied to the package-level 2D Data Matrix). Small dispensers may keep using current methods until November 27, 2027.

Pharmacy Obligations at Receipt

A dispenser (pharmacy) must:

Verify authorization of the trading partner from whom it purchases.

Receive TI and TS with each incoming shipment of a covered product. Pharmacies may receive the data electronically through a wholesale distributor portal rather than paper-in-hand with each shipment, provided the data is accessible within two business days of a request.

Not accept product if tracing information is missing or incomplete. The pharmacy must either return the product or quarantine it and work with the trading partner to obtain the missing data.

Retain tracing data for six years (or longer if required by state law).

Investigate suspect products promptly.

Suspect and Illegitimate Product Handling

A suspect product is one for which the pharmacy has reason to believe it is counterfeit, diverted, stolen, intentionally adulterated, intended for fraudulent transaction, or otherwise unfit for distribution such that use of the product would result in serious adverse health consequences or death.

An illegitimate product is one that the pharmacy has confirmed through investigation to be counterfeit, diverted, stolen, intentionally adulterated, or otherwise unfit.

Required workflow:

Quarantine the suspect product physically or electronically so it is not dispensed.

Investigate promptly—check TI/TS, contact the trading partner, examine packaging, verify lot and NDC against FDA records.

If confirmed illegitimate : notify FDA (through FDA's Form 3911 or the appropriate notification mechanism) and the immediate trading partner within 24 hours of confirmation.

If cleared as legitimate : release the product and document the investigation outcome.

November 27, 2024: End of FDA's Stabilization Period

The DSCSA was phased in over a decade. The FDA granted a stabilization period that ended November 27, 2024 . FDA then exempted trading partners by type: manufacturers and repackagers to May 27, 2025, wholesale distributors to August 27, 2025, dispensers with 26 or more full-time pharmacists and technicians to November 27, 2025, and small dispensers to November 27, 2027. After those dates:

TI and TS must be exchanged in a secure, interoperable electronic form (small dispensers may keep using current methods until November 27, 2027).

Pharmacies must be able to capture and retain package-level data (e.g., 2D Data Matrix scans).

FDA may take enforcement action for non-compliant transactions.

Some drugs fall outside the DSCSA tracing requirements because the statute's definition of product excludes them (21 U.S.C. § 360eee(13)): blood or blood components for transfusion, certain radioactive drugs, imaging drugs, certain intravenous fluid products, medical gases, homeopathic drugs, and drugs compounded in compliance with section 503A or 503B.

State Overlays and Inspections

Pennsylvania wholesale distributor licensure is administered under the Prescription Drug Wholesale Distributor Licensure Act and related DOH rules. A pharmacy's permit inspection under 49 Pa. Code § 27.11 includes verifying that the pharmacy acquires product only from authorized trading partners. Out-of-state pharmacies shipping into Pennsylvania must register with the PA Board, and their wholesale distributor relationships must be documented.

Exam Traps and Scenarios

A wholesaler ships product without TI/TS — the pharmacy must not stock the product for dispensing; quarantine or return and obtain the missing tracing before dispensing.

2D barcode scan fails on receipt — investigate; the failure does not automatically make the product illegitimate, but the pharmacy cannot dispense it until cleared.

Product tracing must be retained six years — even though Pennsylvania pharmacy records generally must be retained two years, DSCSA tracing data has a longer federal retention.

Suspect product confirmed as illegitimate on Friday — notify FDA and the trading partner within 24 hours; the 24-hour clock starts at confirmation, not at the next business day.

A pharmacy buys stock from another pharmacy — the selling pharmacy needs a wholesale distributor license unless a 21 U.S.C. § 353(e)(4) exclusion applies (e.g., intracompany or common-control transfers, minimal quantities to a practitioner for office use); a sale to fill a specific patient need does not require TI or a TS (21 U.S.C. § 360eee-1(d)(1)(A)(ii)).

Compounded products from a 503B outsourcing facility — a drug compounded in compliance with section 503B is excluded from the DSCSA definition of product (21 U.S.C. § 360eee(13)), so DSCSA product tracing does not apply to it.